Carsten Browall proposed as new Chairman of Vitrolife AB (publ)

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:

The Election Committee of Vitrolife AB (publ) has proposed Carsten Browall as the new Chairman of the Board. Carsten Browall is today a member of the company's Board and he has many years of experience in medical device and the healthcare sector.

Vitrolife's Election Committee today announced that it proposes that the Annual General Meeting elect Carsten Browall as the company's new Chairman of the Board. Carsten Browall has been a member of the Vitrolife Board since 2012 and has many years of experience from executive positions within medical device and the healthcare sector, amongst other things from Unfors RaySafe, Mölnlycke Health Care, Nobel Biocare and Capio.

"It is an honour to be asked to take over the position of Chairman and it will be immensely exciting to continue the work on Vitrolife's successful journey together with the Board and the executive management," says Carsten Browall.

The present Chairman of the Board, Patrik Tigerschiöld, has declined reelection after 13 years on the Board and 11 years as its Chairman.

"It has been a very successful period for Vitrolife and it now feels natural to hand over the Chairman's gavel to Carsten Browall, who I am convinced is the right person to lead the Board in the company's next phase. I would like to make clear that my decision to leave the Board shall in no way be seen as Bure Equity, which is the largest owner, having a changed view of its shareholding in Vitrolife," says Patrik Tigerschiöld.

Gothenburg, March 25, 2013

VITROLIFE AB (publ)

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.